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Introduction
Aspergillus fumigatus is an ubiquitous fungus that, together with other saprophytic fungi, plays a significant role in 
the environmental carbon and nitrogen biomass balance [1]. However, conidia that are released by A. fumigatus into 
the air are a threat to humans with an immunocompromised status, as they may cause life-threatening infections. 
Vornberg and Gastmeier showed that even concentrations of Aspergillus spp. of below 1 colony-forming unit/m3 were 
sufficient to cause infection in high-risk patients in hospitals [2]. They reviewed 53 studies with a total of 458 patients. 
In 356 patients, the lower respiratory tract was the primary site of Aspergillus infection. Species identified most often 
were A. fumigatus  and A. flavus [2]. 
Pathogenesis
Aspergillus may cause a spectrum of diseases in humans including (a) allergic diseases, such as allergic bronchopulmo-
nary aspergillosis (ABPA) and allergic pulmonary alveolar diseases, (b) colonization of air spaces, such as fungus balls in 
pre-existing pulmonary cavities (aspergilloma) or sinuses, endobronchial colonization and (c) invasive forms. The colo-
nization and invasion of the respiratory airway in immunocompromised patients starts primarily through the inhalation 
of conidia. Once the first line of innate immune defense consisting of mucus barrier and resident alveolar macrophages 
is overcome, life threatening Aspergillus diseases can be caused [3]. 
Figure 1. Model of Aspergillus fumigatus interactions with pulmonary epithelial cells and vascular endothelial cells during angioin-
vasion and dissemination (Figure adapted from Filler et al., 2006)[4]. 
Invasive aspergillosis (IA) can be divided into diseases caused after pulmonary entrance and those with a non-pulmo-
nary portal. Pneumonia is the most frequent manifestation of invasive aspergillosis, which can spread from the lungs 
to the brain and other organs. 
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 Filler and colleagues presented a model about how IA might occur [4]. According to this model the inhaled airborne 
conidia adhere to pulmonary epithelial cells and are endocytosed. Within the epithelial cells, the conidia germinate 
to form hyphae which then escape from the epithelial cells (Figure 1, A-E). Next, the hyphae invade the surface of the 
endothelial cells causing cell damage (Figure1, F-H). Dissemination with hyphal fragments occurs via blood circulation 
and then the fungal agents adhere to the luminal endothelial cell surface (I) before invading these cells (J). Invasion into 
the endothelial cell causes severe cell damage (K) and extravascular invasion of organs (L) [5,6,7]
Antifungal compounds used for treatment of aspergillosis
IA is a very frequent infection in neutropenic patients. The mortality rate ranges from 30 to 80%, despite the advances 
in transplant medicine and the development of new antifungal agents [5,6,7]. Additionally, there are clinical studies 
which show that IA remains the most commonly identified invasive fungal infection, but rates of survival in patients 
with IA appear to have improved [8,9]. Mono- and poly-centric studies performed in France, Spain, and North America 
showed similar trends of improving outcomes over time [10,11,12]. To further understand the differences in patient 
survival rate, controlled epidemiological studies are needed to be conducted. 
There are a limited number of antifungal agents available to treat IA. The following compounds are licensed in most 
countries for the management of IA: itraconazole (ITZ), voriconazole (VCZ), posaconazole (POSA), amphotericin B (D-
AMB) and its lipid formulations (ABLC), L-AMB and AMB colloidal dispersion (AMBCD), and caspofungin (CAS). Table 1 
shows the clinical guideline recommended by Walsh et al.[13]
13
Table1: Summary of recommendations for the treatment of aspergillosis (modified from Walsh et. al.[13])
Treatment recommendations
Condition Primary Alternative
Invasive pulmonary aspergillosis
VCZ (6 mg/kg i.v. every 12 h for 
1 day, followed by 4 mg/kg i.v. 
every 12h; oral dosage is 200 mg 
every 12 h)
L-AMB (3–5 mg/kg/day i.v.), 
ABLC (5 mg/kg/day i.v.), CAS 
(70 mg day 1 i.v. and 50 mg/day 
i.v. thereafter), micafungin (i.v. 
100–150 mg/day; dose not es-
tablished),
POSA (200 mg QID initially, then 
400 mg BID PO after stabilization 
of diseased), ITZ (dosage de-
pends upon formulation)
Invasive sinus aspergillosis
Similar to invasive pulmonary 
aspergillosis
Similar to invasive pulmonary 
aspergillosis
Tracheobronchial aspergillosis
Similar to invasive pulmonary 
aspergillosis
Similar to invasive pulmonary 
aspergillosis
Chronic necrotizing pulmonary 
aspergillosis (subacute invasive 
pulmonary aspergillosis)
Similar to invasive pulmonary 
aspergillosis
Similar to invasive pulmonary 
aspergillosis
Aspergillosis of the CNS
Similar to invasive pulmonary 
aspergillosis
Similar to invasive pulmonary 
aspergillosis
Aspergillus infections of 
the heart (endocarditis, 
pericarditis,and myocarditis)
Similar to invasive pulmonary 
aspergillosis
Aspergillus osteomyelitis and
septic arthritis
Similar to invasive pulmonary 
aspergillosis
Aspergillus infections of the eye 
(endophthalmitis and keratitis)
Aspergillus infections of the eye 
(endophthalmitis and keratitis)
Intraocular AMB indicated with 
partial vitrectomy
Aspergillus peritonitis
Similar to invasive pulmonary 
aspergillosis
Empirical and preemptive anti-
fungal therapy
For empirical antifungal therapy, 
L-AMB (3 mg/kg/day i.v.), CAS 
(70 mg day 1 i.v. and 50 mg/day 
i.v. thereafter), ITZ (daily 200 mg 
i.v. or 200 mg BID), VCZ (6 mg/kg 
i.v. every 12h for 1 day, followed 
by 3 mg/kg i.v. every 12 h; oral 
dosage is 200 mg every 12 h)
Prophylaxis against invasive as-
pergillosis
POSA (200 mg every 8h)
ITZ (200 mg/12 h i.v. for 2 days, 
then 200 mg /24 h i.v.) or ITZ 
(200 mg PO/12 h); micafungin 
(50 mg/day)
Aspergilloma No therapy or surgical resection
ITZ or VCZ; similar to invasive 
pulmonary aspergillosis
Chronic cavitary pulmonary as-
pergillosis
ITZ or VCZ
Similar to invasive pulmonary 
aspergillosis
Allergic bronchopulmonary as-
pergillosis
ITZ
Oral VCZ (200 mg PO/12 h) or 
POSA (400 mg PO BID)
Allergic aspergillus sinusitis None or ITZ Few data on other agents
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In vitro susceptibility testing in the clinical diagnostic laboratory
The quantification of the level of microbial susceptibility to a drug occurs by determining the minimal inhibitory con-
centration (MIC), which is the lowest concentration required to obtain (near) significant growth inhibition of patho-
gens. The term resistance applies to pathogen populations that tolerate higher concentrations than the MIC and are 
able to grow at a given antimicrobial agent concentration. (http://www.eucast.org). Moreover, the pathogen is con-
sidered to be clinically resistant when an approved standard dosing regimen leads to a higher probability of failed re-
sponse. Pathogens can differ in their susceptibility to different drugs. Consequently, they may show resistance to one 
drug, but may be susceptible to another. Usually, resistant strains are mutants; this means they have acquired a genetic 
change that causes loss of susceptibility to a given compound or class of anti-infective agents. Therefore, susceptibility 
testing is used not only for the selection of the drug that is most likely to be active clinically, but is also used to detect 
resistance (http://www.eucast.org). For the determination of resistance based on MIC testing, epidemiological cutoff 
values are often used. These are focused on separating isolates in the normal wild-type population from those of a 
non-wild type phenotype. The latter are considered to have acquired mechanisms that reduce their normal susceptibil-
ity to a certain compound. Epidemiological cutoffs do not take into account factors such as dosages, pharmacokinetics, 
or clinical efficacy (pharmacodynamics; see below), which are considered for clinical breakpoints, but instead aims to 
optimize the detection of isolates with acquired resistance [14,15]. 
With regards to clinical breakpoints, the MIC factor plays the very important role in predicting the efficacy of a drug. 
The development of clinical breakpoints requires MIC data, pharmacokinetic (PK) and pharmacodynamic (PD) informa-
tion, and most importantly outcome data from clinical efficacy trials [15,16]. Taking this information together, interpre-
tative criteria for patients can be developed [17]. The clinical breakpoints serve as a tool to determine the likelihood of 
therapeutic response when patients are treated with an agent at the approved standard dosages. Accordingly, patients 
with infections caused by strains with an MIC below the breakpoint are considered treatable (susceptible strains), 
while those infected with a strain with an MIC above the breakpoint have a high probability that they will not respond 
to therapy (resistant strains) [15]. Thus, the MIC of a strain helps clinicians to decide which drug they will use for treat-
ment.
In mycology, two MIC methodologies are considered to be well standardized and clinically validated for fungal sus-
ceptibility testing: a) the CLSI-M38A2 method (Clinical and Laboratory Standards Institute or CLSI; formerly, National 
Committee for Clinical Laboratory Standards (NCCLS)) [18] and b) the EUCAST method (European Committee on Anti-
microbial Susceptibility Testing) [19]. Although these methodologies are similar, there are some technical differences 
(Table 2).
Table 2: Differences between the two conventional MIC testing methods for A. fumigatus.
Test Parameter CLSI M38-A2 EUCAST
Medium RPMI 1640 RPMI 1640, 2% glucose
Inoculum density 0.4-5x104 CFU/ml 2-5x105 CFU/ml
Plates Microdilution 96 U-shaped wells Microdilution 96 flat-bottom wells
Endpoint and Read-
ing
100 % visual 100 % visual
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Epidemiological cutoffs for azoles and A. fumigatus
There is no standard method to determine epidemiological cutoff values (ECVs). As a consequence different authors 
use different methods. ECVs for azoles using the EUCAST method were defined by Rodriguez-Tudela et al. The group 
found ECVs for itraconazole, voriconazole, and ravuconazole for the wild-type populations of A. fumigatus less than 
or ≤ to 1 mg/L and for posaconazole at MIC of ≤0.25 mg/L, including 93.4% of the isolates [20]. Next, Pfaller et al 
confirmed these results by using the CLSI reference method for the establishment of the wild-type MIC distribution 
and epidemiological cutoff values for the azoles [21]. Recently, Espinel-Ingroff and colleagues contradicted these re-
ports by using the ≥99% inclusion methodology to define ECVs [22]. Accordingly, 95% of A. fumigatus was inhibited 
by posaconazole at concentrations of 0.25 mg/L, but 99% was inhibited with 0.5 mg/L. In the case of itraconazole and 
voriconazole, the ECVs remained at 1 mg/L (98.8% - 97.7%), respectively. The MIC studies were performed in five in-
dependent laboratories in Europe and the United States and showed that the modal (most frequent observed) values 
were either the same as or one dilution higher than those in previous ECV reports; this indicated discrepancies in MIC 
reading (±1 dilution). These differences indicate that although considerable progress has been made with the develop-
ment of the CLSI and EUCAST methods, optimization is still required. Furthermore, the criteria used to establish ECVs 
for filamentous fungi are based on arbitrary statistical calculations which may lead to discrepant results. Thus, a more 
objective way to calculate ECV statistics than the aforementioned assumptions is required in order to obtain accurate 
and reproducible ECVs. 
Azole resistance in Aspergillus fumigatus
The ergosterol pathway
As aforementioned, Aspergillus diseases are usually treated with triazoles. Azoles are divided into two major classes: a) 
the imidazoles represented by ketoconazole and miconazole and b) the triazoles represented by the clinically licensed 
drugs fluconazole, itraconazole, voriconazole and posaconazole, and the investigational agents albaconazole (UR 9825) 
[23] and isavuconazole (BAL-4815) [24]. Triazoles prevent fungal growth by inhibiting the major checkpoint of the fun-
gal cell membrane, the sterol 14a-demethylase (Figure 2). 
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Figure 2. Targets in the ergosterol pathway for different classes of antifungal compounds.
Sterol 14a-demethylase (CYP51), which belongs to the cytochrome P450 family, is the only enzyme widely conserved 
in different biological kingdoms [25]Mukogawa Women&apos;s University, Nishinomiya, 663-8719, Japan.</auth-
address><titles><title>Sterol 14-demethylase P450 (CYP51 and is considered to be the most ancient member of this 
super family [26,27]. It catalyzes the oxidative removal of the 14a-methyl group of lanosterol and 24-methylene-24,25-
dihydrolanosterol in yeast and fungi to give D14,15-desaturated intermediates in ergosterol biosynthesis (Figure 2). 
During the catalytic cycle, a substrate undergoes three successive monooxygenation reactions, resulting in the forma-
tion of 14-hydroxymethyl, 14-carboxaldehyde, and 14-formyl derivatives followed by elimination of formic acid with in-
troduction of a 14, 15 double bond [28,29,30]. Triazoles are designed to inhibit the function of sterol 14a-demethylase, 
resulting in the blockage of the ergosterol biosynthesis pathway. Ergosterol serves as a bioregulator of membrane fluid-
ity and asymmetry and consequently of membrane integrity in fungal cells. The lack of ergosterol causes disruption of 
the fluidity of the membrane and fungal cell death occurs. 
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Recent reports indicate that acquired resistance to azoles is emerging in A. fumigatus. The emergence of resistance has 
led to an increasing number of investigations into the underlying mechanisms. Most of these studies have focused pri-
marily on the gene encoding 14a-demethylase, the cyp51A gene [31,32,33,34,35,36]. A number of genetic alterations 
have been described in clinical isolates from patients with Aspergillus diseases [37,38,39,40,41,42]. The frequently 
characterized coding hotspot regions of cyp51A are at codons 54, 220, and 98 (Figure 3). 
Figure 3. Positional distribution of the most frequent mutational hot spots in the open reading frame and the 5’ - regulatory region 
of cyp51A leading to azole resistance (modified from Verweij et al., 2009) [43].
Development of azole resistance in patients
Azole resistance may develop when A. fumigatus is exposed to azole compounds. Resistance development therefore 
may occur during long-term azole therapy of patients with Aspergillus disease. A number of studies have reported this 
route of resistance development [44]. Four A. fumigatus isolates were serially recovered from a single patient within 
one year by Bellete and colleagues [44]. During this year the patient received voriconazole, caspofungin, and liposomal 
amphotericin B. Susceptibility testing showed that the first isolate was susceptible to all antifungals, but the second 
strain recovered one month later had elevated MICs to itraconazole and voriconazole. The third isolate obtained after 
two months of therapy showed an MIC of 8 mg/L of itraconazole, despite the fact that the patient had not received 
this drug, and a marked increase in the MIC of voriconazole (MIC = 2 mg/L). The fourth isolate exhibited an MIC of > 32 
mg/L of voriconazole. It appeared that posaconazole remained active against these isolates. Sequencing of the cyp51A 
gene of all isolates revealed that only the fourth one was carrying the G448S mutation. Howard et al. also reported the 
acquisition of resistance to itraconazole (8 mg/L), voriconazole (8 mg/L) and posaconazole (4 mg/L) after long-term 
treatment of a patient with bilateral chronic cavitary aspergillosis with aspergillomas. This resistance was accounted 
for by the G138C substitution [45]. Clinical cases reported for the development of cyp51A-mediated azole resistance, 
in particular, similar to those described above, are increasing in numbers in recent years [46]. 
Epidemiology of azole resistance in Aspergillus fumigatus
The first epidemiological report about azole resistance in A. fumigatus and its spread came from the Netherlands 
[40]. The prevalence of itraconazole resistance was investigated in 1912 clinical A. fumigatus isolates collected from 
1219 patients in the University Medical Centre over a period of 14 years. The spread of resistance was investigated 
by analyzing 147 A. fumigatus isolates from 101 patients, from 28 other medical centers in The Netherlands, and 317 
isolates from 6 other countries. ITZ-resistant isolates were found in 32 of 1219 patients (Figure 4, panel A). All cases 
were observed after the year 1999 with an annual prevalence of 1.7 to 6%. The ITZ-resistant isolates also showed a 
reduced susceptibility to voriconazole, ravuconazole, and posaconazole (Figure 5). A dominant resistance mechanism 
was found in 94% of isolates consisting of the substitution of leucine to histidine at codon 98 together with a combina-
tion of a 34 bp tandem repeat in the promoter region (TR
34
/L98H). ITZ resistance was found in isolates from 13 patients 
(12.8%) from 9 other medical centers in The Netherlands, of which 69% harbored the TR/L98H substitution, and in 6 
isolates originating from 4 other countries. Furthermore, from 2007 to 2009, approximately 2,062 isolates from 1,385 
patients were screened for ITZ resistance and the prevalence of resistance to this compound in A. fumigatus in the 
patient cohort was 5.3% (range 0.8%-9.5%). The study revealed that patients with a hematologic or oncologic disease 
were more likely to harbor an azole-resistant isolate than other
F-Helix G-Helix
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                                                 A                  B
Figure 4. Azole resistance in clinical Aspergillus fumigatus isolates received from 1994–2007 in the Netherlands and UK. (panel A: 
from Snelders E. et al., 2008 and panel B: Howard SJ et al., 2009).
patient groups. Interestingly, most patients (64%) from whom a resistant isolate was identified were azole naive, and 
the case-fatality rate of patients with azole-resistant invasive aspergillosis was 88% [47]. 
An epidemiological study was also conducted by Howard et al in the UK (Figure 4, panel B)[48]lectronic-resource-
num><language>eng</language></record></Cite></EndNote>. In a clinical collection of 519 A. fumigatus isolates, the 
frequency of ITZ resistance was 5%, showing a significant increase since 2004. Of the 34 ITZ-resistant isolates they 
studied, 65% were cross-resistant to voriconazole and 74% were cross-resistant to posaconazole. In this study, 13 of 14 
patients evaluated had prior azole exposure; 8 failed therapy and 5 failed to improve, but remained stable. In total 18 
amino acid alterations were identified in the target enzyme, Cyp51A. 
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Figure 5. Distribution of proportions of MICs of 32 ITZ+ (fungal growth in the presence of 8 mg/l of ITZ) A. fumigatus isolates (Blue 
Bars) and 115 ITZ− (no growth on ITZ containing slants) controls (Red Bars) of ITZ (left upper panel), Voriconazole (right upper 
panel), ravuconazole (left lower panel), and posaconazole (right lower panel). Left x-axis represents the proportion of isolates and 
on the right x-axis the MIC distribution is shown (from Snelders E. et al., 2008) 
All previous reports show that acquired resistance may threaten the use of azole antifungals and this is worrisome be-
cause this class of agents is the only one on hand for the management of IA. In general, early diagnosis of IA is difficult 
to achieve due to the lack of technical standardization and the major disadvantage of poor specificity of all currently 
available early-stage diagnostic markers [49]. Given that the development of azole resistance in A. fumigatus is increas-
ing the difficulties of clinical management, there may be a need to re-evaluate the clinical efficacy of azoles. This can be 
obtained through investigations in the pharmacokinetic and pharmacodynamic properties of antifungal agents against 
infections with azole resistant strains. 
Optimizing antifungal treatment: parameters of predictive efficacy
The factors that determine the clinical outcome of fungal infections are: 1) host immune state 2) pathogen properties 
(for example susceptibility of the fungus to the antimicrobial agent) 3) the site of the infection 4) the timing of diagno-
sis and 
Figure 6. Determinants for outcome in invasive mycoses [50].
initiation of antifungal therapy 5) the management of the infection source and 6) the appropriate dosing regimen of 
the most potent and safe antifungal drug (Fig. 6) [50]Appropriate application of knowledge about the pharmacokinet-
ics and pharmacodynamics of drugs is a powerful tool against infections. In the last few years, the determination of 
the PK/PD magnitude has been gaining interest and popularity among clinicians [50,51]. This may be vital in preventing 
fungal resistance in the face of its emergence [52].
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Clinical impact of pharmacokinetics and pharmacodynamics
Pharmacokinetic studies investigate how the body handles drugs, including absorption, distribution, metabolism and 
elimination. Pharmacodynamics examines the relationship between an antimicrobial and organism over time, deter-
mining the effects of variations in drug concentrations on organism killing and growth dynamics [53]. Three PK/PD 
indices (Figure 7), such as the area under the serum concentration time curve (AUC) over minimum inhibitory concen-
tration (MIC) ratio (AUC/MIC), 
Figure 7. The pharmacokinetic and pharmacodynamic indices.
peak serum level/MIC ratio (Peak/MIC), or time that serum levels remain above the MIC (T > MIC), have been shown 
to be the primary determinants of in-vivo efficacy and to vary in importance for different classes of drugs [54]. The 
PK/PD indices are important for predicting therapeutic outcome against multiple infectious agents and for providing 
insight in preventing the emergence of drug resistance [55,56]. The time course of antimicrobial activity is dependent 
on the drug’s PKs and two PD characteristics: a) the rate of organism killing and the effect of increasing drug concen-
trations on the rate and extent of killing and b) the presence or absence of persisting inhibitory effects on organism 
growth after drug levels have fallen below the MIC [50]. Nowadays, MIC testing is useful in guiding the selection of the 
antifungal agent for treatment, whereas PD investigations provide information about the design of the dosing regimen, 
including the dose and the frequency of administration of a drug. The determination of the amount of drug needed 
for efficacy is relative to the MIC of the infecting organism. In efficacy studies of candidiasis the PD magnitude usually 
describes the dose–response relationship for an antifungal agent against numerous organisms with widely varying 
MICs[57,58,59] and in the case of the triazole class the 24h AUC/MIC index was reported to be strongly associated 
with efficacy [60,61,62,63]. Furthermore, Andes et al. highlighted in efficacy studies with the triazoles posaconazole, 
voriconazole, fluconazole and ravuconazole that, for the examination of PD relationships, it is necessary to consider the 
protein binding. The protein binding for the aforementioned azoles ranges from 10 to 99% [57,60,61,64]. Accordingly, 
Andes and colleagues demonstrated that total 24h AUC/MIC values associated with effective concentrations reaching 
50% efficacy (EC
50
 or EI
50
) varied more than 100-fold for total drug between the azoles studied. When considering free-
drug concentrations, the 24h fAUC/MIC values varied less than four-fold and were close to a value of 25 for each azole 
[63]. This indicates that the free AUC/MIC is an index of high importance when dealing with azoles and should always 
be taken into consideration. 
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Biological consequences of antifungal resistance in fungi 
Long term and excessive use of anti-infectives can lead to acquisition of antimicrobial resistance. Specifically, in bac-
teria it was shown that low concentrations of antibiotics can generate multi-drug resistance due to the increase of 
the mutation rate [65]. It is well known that development of antimicrobial resistance often comes with a fitness cost 
whereby the resistant mutants usually have a lower fitness than its sensitive relatives. The majority of resistance 
mechanisms are associated with a fitness cost that is typically observed as decreased virulence or reduced growth rate. 
The degree of this cost usually influences the rate of development of resistance and the stability of the resistance [66]. 
In the last decade, the effect of resistance on virulence has been also observed in fungi. For example, FKS1 mutations 
were found to be associated with resistance to echinocandins in Candida albicans thereby contributing to significant 
fitness and/or virulence costs. The mutants presented a thickened, chitin-rich cell wall, impaired filamentation and in-
duction of an impaired inflammatory response [67]. Similarly, disruption of the multidrug resistance gene (CaMDR1) in 
C. albicans resulted in mutant strains that colonized mouse kidneys to very high levels but were dramatically reduced 
in their virulence [68]. Fluconazole-induced petite mutations in C. glabrata led to reduction in virulence. This was ap-
parently related to the slower growth of the resistant strains, which demonstrated longer periods of latency and longer 
generation times, than those of their susceptible parents [69]. 
The first association between azole drug resistance and its impact in the virulence of A. fumigatus was demonstrated 
by Willger and colleagues [70]. A sterol-regulatory element binding protein, SrbA and its homologue Sre1 in yeast were 
reported to be required for hypoxia adaptation and ergosterol biosynthesis [71]. Loss of SrbA of the fungus resulted in 
growth incapacity of A. fumigatus in a hypoxic environment and inability to cause fatal infections in two distinct murine 
models of invasive pulmonary aspergillosis. Further examination of the SrbA null mutant revealed that SrbA plays a 
critical role in resistance to the azole class of antifungal drugs. Scanning through the literature reveals that, although 
a number of molecular resistance mechanisms in fungi are described in detail, the potential accompanying virulence 
changes and impact on clinical outcome are only barely investigated. 
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Outline of this thesis
Given that resistance mechanisms affect the activity of multiple medical triazoles, it is important to investigate if the 
azoles have a role in the treatment of isolates harboring resistance mechanisms. The current thesis explores the rela-
tionships among PK, MIC, and treatment outcome against azole-resistant A. fumigatus isolates with different cyp51A 
substitutions. The determination of dose and exposure-response relative to the MIC required for efficacy of posacon-
azole against three clinical A. fumigatus isolates with various MICs and a wild-type are described in chapter 2. The 
exposure-response relationship to MIC for voriconazole against three clinical A. fumigatus isolates with various MICs 
and cyp51A mutations and a wild-type is described in chapter 3. The determination of epidemiological cutoff values 
(ECV) to separate wild-type isolates from isolates with reduced susceptibility to voriconazole, posaconazole, and ITZ is 
described in chapter 4 and the results from chapter 2 and chapter 3 led to the extrapolation and proposal of clinical 
breakpoints for A. fumigatus. In chapter 5 we investigated a) the efficacy of posaconazole, anidulafungin, and their 
combination against a set of isogenic clinical A. fumigatus isolates that harbored a novel resistance mechanism, which 
regulated cyp51A expression, and b) the impact of resistance on virulence. In chapter 6, we investigated a number 
of azole-resistance mechanisms (cyp51A and non-cyp51A) and their potential relationship with changes in virulence. 
Thereby, we developed the composite survival index (CSI) as a measure of the virulence properties of A. fumigatus. 
23
References
1. Gugnani HC (2003) Ecology and taxonomy of pathogenic aspergilli. Front Biosci 8: s346-357.
2. Vonberg RP, Gastmeier P (2006) Nosocomial aspergillosis in outbreak settings. J Hosp Infect 63: 246-254.
3. Crameri R, Blaser K (2002) Allergy and immunity to fungal infections and colonization. Eur Respir J 19: 151-157.
4. Filler SG, Sheppard DC (2006) Fungal invasion of normally non-phagocytic host cells. PLoS Pathog 2: e129.
5. Arikan S, Rex JH (2002) New agents for the treatment of systemic fungal infections--current status. Expert Opin 
Emerg Drugs 7: 3-32.
6. Stevens DA (2009) Clinical aspergillosis for basic scientists. Med Mycol 47 Suppl 1: S1-4.
7. Maschmeyer G, Haas A, Cornely OA (2007) Invasive aspergillosis: epidemiology, diagnosis and management in im-
munocompromised patients. Drugs 67: 1567-1601.
8. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA (2007) Invasive aspergillosis following hematopoietic cell trans-
plantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44: 531-540.
9. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, et al. (2009) Epidemiology and outcome of invasive fungal 
infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal 
Therapy (PATH) Alliance registry. Clin Infect Dis 48: 265-273.
10. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, et al. (2008) Factors associated with overall 
and attributable mortality in invasive aspergillosis. Clin Infect Dis 47: 1176-1184.
11. Cordonnier C, Ribaud P, Herbrecht R, Milpied N, Valteau-Couanet D, et al. (2006) Prognostic factors for death due to 
invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive 
patients at French transplantation centers. Clin Infect Dis 42: 955-963.
12. Parody R, Martino R, Sanchez F, Subira M, Hidalgo A, et al. (2009) Predicting survival in adults with invasive as-
pergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: 
Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol 
84: 571-578.
13. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, et al. (2008) Treatment of aspergillosis: clinical 
practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327-360.
14. Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, et al. (2003) European harmonization of MIC 
breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52: 145-148.
15. Mouton JW (2003) Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin 
North Am 17: 579-598.
16. Mouton JW (2002) Breakpoints: current practice and future perspectives. Int J Antimicrob Agents 19: 323-331.
17. Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, et al. (2012) The role of pharmacokinetics/pharmacodynam-
ics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 18: E37-45.
18. CLSI Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved stan-
dard—second edition. CLSI document M38 –A2. Clinical and Laboratory Standards Institute, Wayne, PA.
19. EUCAST. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concen-
trations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982–984.
20. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, et al. (2008) Epidemiological cut-
offs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 52: 2468-2472.
21. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, et al. (2009) Wild-type MIC distributi on and epide-
24
miological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Labora-
tory Standards Institute broth microdilution methods. J Clin Microbiol 47: 3142-3146.
22. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, et al. (2010) Wild-type MIC distributions and epi-
demiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method 
(M38-A2 document). J Clin Microbiol 48: 3251-3257.
23. Ramos G, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL (1999) In-vitro comparative activity of UR-9825, itra-
conazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 44: 283-286.
24. Odds FC (2006) Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal. Curr Opin Investig Drugs 
7: 766-772.
25. Yoshida Y, Aoyama Y, Noshiro M, Gotoh O (2000) Sterol 14-demethylase P450 (CYP51) provides a breakthrough for 
the discussion on the evolution of cytochrome P450 gene superfamily. Biochem Biophys Res Commun 273: 
799-804.
26. Aoyama Y, Noshiro M, Gotoh O, Imaoka S, Funae Y, et al. (1996) Sterol 14-demethylase P450 (P45014DM*) is one 
of the most ancient and conserved P450 species. J Biochem 119: 926-933.
27. Nelson DR (1999) Cytochrome P450 and the individuality of species. Arch Biochem Biophys 369: 1-10.
28. Trzaskos JM, Fischer RT, Favata MF (1986) Mechanistic studies of lanosterol C-32 demethylation. Conditions which 
promote oxysterol intermediate accumulation during the demethylation process. J Biol Chem 261: 16937-
16942.
29. Shafiee A, Trzaskos JM, Paik YK, Gaylor JL (1986) Oxidative demethylation of lanosterol in cholesterol biosynthesis: 
accumulation of sterol intermediates. J Lipid Res 27: 1-10.
30. Aoyama Y, Yoshida Y, Sonoda Y, Sato Y (1989) Deformylation of 32-oxo-24,25-dihydrolanosterol by the purified cyto-
chrome P-45014DM (lanosterol 14 alpha-demethylase) from yeast evidence confirming the intermediate step 
of lanosterol 14 alpha-demethylation. J Biol Chem 264: 18502-18505.
31. Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, et al. (2001) Acquired itraconazole resistance in Aspergillus 
fumigatus. J Antimicrob Chemother 47: 333-340.
32. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, et al. (2007) A new Aspergillus fumigatus re-
sistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A 
alterations. Antimicrob Agents Chemother 51: 1897-1904.
33. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL (2004) Substitutions at methio-
nine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in 
vitro to azole antifungal drugs. Antimicrob Agents Chemother 48: 2747-2750.
34. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL (2001) Identification of two different 14-alpha 
sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. 
Journal of clinical microbiology 39: 2431-2438.
35. Mellado E, Garcia-Effron G, Buitrago MJ, Alcazar-Fuoli L, Cuenca-Estrella M, et al. (2005) Targeted gene disruption 
of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. 
Antimicrob Agents Chemother 49: 2536-2538.
36. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH (2000) A comparative study of the in vitro susceptibili-
ties of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, 
voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46: 229-234.
37. Dannaoui E, Garcia-Hermoso D, Naccache JM, Meneau I, Sanglard D, et al. (2006) Use of voriconazole in a patient 
with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus. J Med Microbiol 55: 
1457-1459.
38. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, et al. (2009) Azole-resistant central nervous sy-
stem aspergillosis. Clin Infect Dis 48: 1111-1113.
25
39. Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE, et al. (2009) Multiple-azole-resistant Aspergillus 
fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term 
oral posaconazole and surgery. Med Mycol 47: 217-220.
40. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, et al. (2008) Emergence of azole resistance in Aspergillus 
fumigatus and spread of a single resistance mechanism. PLoS Med 5: e219.
41. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE (2007) Aspergillosis--and a misleading sensitivity 
result. Lancet 370: 102.
42. Verweij PE, Mellado E, Melchers WJ (2007) Multiple-triazole-resistant aspergillosis. N Engl J Med 356: 1481-1483.
43. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ (2009) Azole resistance in Aspergillus fumigatus: a side-
effect of environmental fungicide use? Lancet Infect Dis 9: 789-795.
44. Bellete B, Raberin H, Morel J, Flori P, Hafid J, et al. (2010) Acquired resistance to voriconazole and itraconazole in a 
patient with pulmonary aspergilloma. Med Mycol 48: 197-200.
45. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, et al. (2006) Multi-azole resistance in Aspergillus fumigatus. 
Int J Antimicrob Agents 28: 450-453.
46. Tashiro M, Izumikawa K, Hirano K, Ide S, Mihara T, et al. (2012) Correlation between triazole treatment history and 
susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother.
47. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, et al. (2011) Clinical implications of azole 
resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 17: 1846-1854.
48. Howard SJ, Cerar D, Anderson MJ, Albarrag A (2009) Frequency and evolution of Azole resistance in Aspergillus 
fumigatus associated with treatment failure. Emerging infectious diseases: 1068-1076.
49. Yeo SF, Wong B (2002) Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Micro-
biol Rev 15: 465-484.
50. Andes D, Pascual A, Marchetti O (2009) Antifungal therapeutic drug monitoring: established and emerging indica-
tions. Antimicrob Agents Chemother 53: 24-34.
51. Dolton MJ, Ray JE, Marriott D, McLachlan AJ (2012) Posaconazole exposure-response relationship: evaluating the 
utility of therapeutic drug monitoring. Antimicrob Agents Chemother 56: 2806-2813.
52. Kohno S, Izumikawa K (2010) Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat 
of azole-resistant Aspergillus infection. Clin Infect Dis 51: 1392-1394.
53. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and 
men. Clin Infect Dis 26: 1-10; quiz 11-12.
54. Andes D (2001) Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory 
tract infections. Curr Opin Infect Dis 14: 165-172.
55. Andes D, Craig WA (1998) In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneu-
moniae: application to breakpoint determinations. Antimicrob Agents Chemother 42: 2375-2379.
56. Levison ME, Levison JH (2009) Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin 
North Am 23: 791-815, vii.
57. Andes D, van Ogtrop M (1999) Characterization and quantitation of the pharmacodynamics of fluconazole in a 
neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43: 2116-2120.
58. Rodriguez MM, Pastor FJ, Sutton DA, Calvo E, Fothergill AW, et al. (2010) Correlation between in vitro activity of 
posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother 54: 
1665-1669.
59. Martel CM, Parker JE, Bader O, Weig M, Gross U, et al. (2010) A clinical isolate of Candida albicans with mutations in 
ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles 
26
and amphotericin B. Antimicrob Agents Chemother 54: 3578-3583.
60. Andes D, Marchillo K, Stamstad T, Conklin R (2003) In vivo pharmacokinetics and pharmacodynamics of a new tri-
azole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47: 3165-3169.
61. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, et al. (2004) Pharmacodynamics of a new triazole, posaconazole, 
in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 48: 137-142.
62. Andes D, van Ogtrop M (2000) In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic 
murine disseminated candidiasis model. Antimicrob Agents Chemother 44: 938-942.
63. Andes D (2004) Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifun-
gal drug resistance. Drug Resist Updat 7: 185-194.
64. Andes D, Marchillo K, Stamstad T, Conklin R (2003) In vivo pharmacodynamics of a new triazole, ravuconazole, in a 
murine candidiasis model. Antimicrob Agents Chemother 47: 1193-1199.
65. Kohanski MA, DePristo MA, Collins JJ (2010) Sublethal antibiotic treatment leads to multidrug resistance via radical-
induced mutagenesis. Mol Cell 37: 311-320.
66. Andersson DI, Hughes D (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Mi-
crobiol 8: 260-271.
67. Ben-Ami R, Kontoyiannis DP (2012) Resistance to echinocandins comes at a cost: the impact of FKS1 hotspot muta-
tions on Candida albicans fitness and virulence. Virulence 3: 95-97.
68. Becker JM, Henry LK, Jiang W, Koltin Y (1995) Reduced virulence of Candida albicans mutants affected in multidrug 
resistance. Infect Immun 63: 4515-4518.
69. Brun S, Dalle F, Saulnier P, Renier G, Bonnin A, et al. (2005) Biological consequences of petite mutations in Candida 
glabrata. J Antimicrob Chemother 56: 307-314.
70. Willger SD, Puttikamonkul S, Kim KH, Burritt JB, Grahl N, et al. (2008) A sterol-regulatory element binding protein 
is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. 
PLoS Pathog 4: e1000200.
71. Chang YC, Bien CM, Lee H, Espenshade PJ, Kwon-Chung KJ (2007) Sre1p, a regulator of oxygen sensing and sterol 
homeostasis, is required for virulence in Cryptococcus neoformans. Molecular Microbiology 64: 614-629.
27
28
29
Chapter 2
Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates 
with Mutations in the cyp51A Gene
Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW, Verweij PE.
Antimicrob Agents Chemother. 2010;54:860-5
Reprinted with permission
30
31
32
33
34
35
36
37
38
39
Chapter 3
Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic      
Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis         
Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW, Verweij PE.
Antimicrob Agents Chemother. 2010;54:4758-64
Reprinted with permission
40
41
42
43
44
45
46
47
48
49
Chapter 4
Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a 
novel mathematical approach incorporating cyp51A.                                                                       
   
Meletiadis J. Mavridou E, , Melchers WJ, Mouton JW, Verweij PE.
        Antimicrob Agents Chemother. 2012;56:2524-9                                                                                                       
Reprinted with permission
50
51
52
53
54
55
56
57
58
59
Chapter 5
       Development of Azole Resistance in Aspergillus fumigatus during Azole   
Therapy Associated with Change in Virulence                       
   
                                                                      
   
Maiken Cavling Arendrup, Eleftheria Mavridou ,Klaus Leth Mortensen, Eveline Snelders,                              
Niels Frimodt-Moller, Humara Khan, Willem J.G. Melchers, Paul E. Verweij .
    PLoS One. 2010;9;5:e10080                                                                                                                                      
Reprinted with permission
60
61
62
63
64
65
66
67
68
69
70
71
Chapter 6
Composite Survival Index to Predict Virulence in Aspergillus fumigatus
Eleftheria Mavridou, Joseph Meletiadis, Pavol Jancura, Saiden Abbas, Maiken C. Arendrup, Willem JG Melchers, Tom 
Heskes, Johan W. Mouton and Paul E. Verweij
Submitted
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
1	  
	   a P
A
;	  p
ul
m
on
ar
y	  
as
pe
rg
ill
os
is
,	  I
A
;	  i
nv
as
iv
e	  
as
pe
rg
ill
os
is
,	  I
P
A
;	  i
nv
as
iv
e	  
pu
lm
on
ar
y	  
as
pe
rg
ill
os
is
,	  A
B
P
A
;	  a
lle
rg
ic
	  b
ro
nc
ho
pu
lm
on
ar
y	  
as
pe
rg
ill
os
is
,	  C
N
S;
	  c
en
tr
al
	  n
er
ve
	  s
ys
te
m
	  	  
b
It
ra
co
na
zo
le
	  a
nd
	  v
or
ic
on
az
ol
e:
	  r
es
is
ta
nt
	  (
R
)	  
M
IC
	  >
	  2
	  m
g/
l,	  
in
te
rm
ed
ia
te
	  (
I)
	  =
	  2
	  m
g/
l,	  
an
d	  
su
sc
ep
ti
bl
e	  
(S
)	  
<	  
2	  
m
g/
l;	  
po
sa
co
na
zo
le
:	  r
es
is
ta
nt
	  (
R
)	  
>	  
0.
5	  
m
g/
l,	  
in
te
rm
ed
ia
te
	  (
I)
	  =
	  0
.5
	  m
g/
l,	  
an
d	  
su
sc
ep
ti
bl
e	  
(S
)	  
<	  
0.
5	  
m
g/
l	  (
28
).
	  
 
Sh
or
t	  
T
an
d
em
	  R
ep
ea
ts
	  
M
IC
	  (
in
te
rp
re
ta
ti
on
b
)(
m
g/
L)
	  
Is
ol
at
e	  
ID
	  n
u
m
b
er
	  
O
ri
gi
n
a 	  
Cy
p5
1A
	  
su
b
st
it
u
ti
on
	  
3
a	  
3
b
	  
3
c	  
4
a	  
4
b
	  
4
c	  
IT
Z	  
V
CZ
	  
P
O
S	  
A
ZN
	  8
19
6	  
P
ro
ve
n	  
IA
	  
N
on
e	  
50
	  
13
	  
7	  
10
	  
27
	  
31
	  
0.
12
5	  
(S
)	  
0.
25
	  (
S)
	  
0.
03
1	  
(S
)	  
V
54
-­‐7
3	  
P
os
si
bl
e	  
IA
	  
N
on
e	  
29
	  
17
	  
7	  
10
	  
26
	  
5	  
0.
25
	  (
S)
	  
0.
5	  
(S
)	  
0.
06
3	  
(S
)	  
V
01
2-­‐
73
	  
P
os
si
bl
e	  
IA
	  
N
on
e	  
37
	  
11
	  
49
	  
10
	  
9	  
8	  
0.
12
5	  
(S
)	  
0.
5	  
(S
)	  
0.
03
1	  
(S
)	  
V
03
0-­‐
17
	  
N
o	  
A
sp
.	  D
is
ea
se
	  
N
on
e	  
29
	  
11
	  
7	  
18
	  
10
	  
8	  
0.
12
5	  
(S
)	  
0.
5	  
(S
)	  
0.
03
1	  
(S
)	  
V
03
3-­‐
63
	  
P
ro
ve
n	  
IA
	  
N
on
e	  
49
	  
11
	  
7	  
13
	  
9	  
5	  
0.
06
3	  
(S
)	  
0.
5	  
(S
)	  
0.
03
1	  
(S
)	  
V
05
0-­‐
05
	  
P
os
si
bl
e	  
IA
	  
N
on
e	  
40
	  
11
	  
26
	  
24
	  
9	  
8	  
0.
12
5	  
(S
)	  
0.
5	  
(S
)	  
0.
03
1	  
(S
)	  
V
52
-­‐0
7	  
P
ro
ve
n	  
IA
	  
N
on
e	  
38
	  
11
	  
46
	  
10
	  
9	  
8	  
0.
12
5	  
(S
)	  
0.
25
	  (
S)
	  
0.
03
1	  
(S
)	  
V
54
-­‐0
9	  
U
nk
no
w
n	  
N
on
e	  
35
	  
11
	  
7	  
25
	  
26
	  
5	  
0.
12
5	  
(S
)	  
0.
25
	  (
S)
	  
0.
03
1	  
(S
)	  
V
52
-­‐7
6	  
P
ro
ve
n	  
IA
	  	  
N
on
e	  
38
	  
11
	  
46
	  
10
	  
9	  
8	  
0.
25
	  (
S)
	  
1	  
(S
)	  
0.
03
1	  
(S
)	  
V
28
-­‐2
9	  
P
ro
ve
n	  
IA
	  
N
on
e	  
25
	  
23
	  
21
	  
14
	  
8	  
5	  
0.
12
5	  
(S
)	  
0.
5	  
(S
)	  
0.
03
1	  
(S
)	  
V
44
-­‐5
8	  
N
o	  
A
sp
	  d
is
ea
se
	  
T
R
/L
98
H
	  
36
	  
9	  
9	  
8	  
10
	  
11
	  
16
	  (
R
)	  
4	  
(R
)	  
1(
I)
	  
V
64
-­‐5
1	  
P
ro
ve
n	  
IA
	  
T
R
/L
98
H
	  
32
	  
9	  
6	  
8	  
10
	  
20
	  
16
	  (
R
)	  
8	  
(R
)	  
1(
I)
	  
V
99
-­‐4
7	  
P
ro
ve
n	  
CN
S	  
IA
	  
T
R
/L
98
H
	  
45
	  
9	  
11
	  
8	  
10
	  
9	  
4	  
(R
)	  
16
	  (
R
)	  
1(
I)
	  
V
64
-­‐7
2	  
P
ro
ve
n	  
IP
A
	  
T
R
/L
98
H
	  
32
	  
9	  
6	  
8	  
10
	  
20
	  
16
	  (
R
)	  
8	  
(R
)	  
1(
I)
	  
V
77
-­‐4
0	  
Ch
ro
ni
c	  
IA
	  
T
R
/L
98
H
	  
10
	  
10
	  
10
	  
8	  
10
	  
14
	  
16
	  (
R
)	  
16
	  (
R
)	  
0.
5	  
(I
)	  
V
79
-­‐7
9	  
U
nk
no
w
n	  
T
R
/L
98
H
	  
31
	  
11
	  
10
	  
8	  
14
	  
20
	  
16
	  (
R
)	  
16
	  (
R
)	  
0.
5	  
(I
)	  
V
80
-­‐0
1	  
A
B
P
A
	  
T
R
/L
98
H
	  
31
	  
11
	  
10
	  
8	  
14
	  
20
	  
16
	  (
R
)	  
16
	  (
R
)	  
0.
5	  
(I
)	  
V
52
-­‐3
5	  
P
ro
ve
n	  
IA
	  
T
R
/L
98
H
	  
84
	  
11
	  
7	  
9	  
10
	  
11
	  
>1
6	  
(R
)	  
2	  
(I
)	  
0.
5	  
(I
)	  
V
45
-­‐0
7	  
P
ro
ve
n	  
IA
	  
T
R
/L
98
H
	  
32
	  
9	  
6	  
8	  
10
	  
20
	  
>1
6	  
(R
)	  
8	  
(R
)	  
0.
5	  
(I
)	  
V
61
-­‐7
6	  
P
ro
ve
n	  
IA
	  
T
R
/L
98
H
	  
85
	  
9	  
10
	  
8	  
11
	  
21
	  
>1
6	  
(R
)	  
4	  
(R
)	  
0.
5	  
(I
)	  
V
94
-­‐1
0	  
P
ro
ve
n	  
IA
	  
46
	  b
p	  
T
R
	  
43
	  
9	  
10
	  
12
	  
9	  
9	  
1	  
(S
)	  
16
	  (
R
)	  
0.
25
	  (
S)
	  
V
28
-­‐7
7	  
A
sp
er
gi
llo
m
a	  
M
22
0I
	  
37
	  
29
	  
33
	  
10
	  
9	  
8	  
>1
6	  
(R
)	  
0.
25
	  (
S)
	  
0.
5	  
(I
)	  
V
59
-­‐2
7	  
A
lle
rg
ic
	  P
A
	  
M
22
0K
	  
	  1
5	  
9	  
	  
18
	  	  
17
	  
9	  
5	  
>1
6	  
(R
)	  
2	  
(I
)	  
>1
6	  
(R
)	  
V
13
-­‐0
9	  
P
ro
ba
bl
e	  
IA
	  
M
22
0V
	  
22
	  
10
	  
30
	  
10
	  
8	  
8	  
>1
6	  
(R
)	  
1	  
(S
)	  
0.
5	  
(I
)	  
V
59
-­‐7
3	  
U
nk
no
w
n	  
cl
in
ic
al
	  
en
ti
ty
	  
G
54
W
	  
14
	  
31
	  
17
	  
8	  
8	  
5	  
>1
6	  
(R
)	  
0.
12
5	  
(S
)	  
>1
6	  
(R
)	  
V
59
-­‐7
2	  
A
sp
er
gi
llo
m
a	  
G
13
8C
	  
36
	  
9	  
9	  
2	  
10
	  
26
	  
>1
6	  
(R
)	  
8	  
(R
)	  
>1
6	  
(R
)	  
V
67
-­‐3
8	  
(S
1)
	  
ch
ro
ni
c	  
P
A
	  
N
on
e	  
	  
47
	  
13
	  
13
	  
	  7
	  
9	  
10
	  
0.
12
5	  
(S
)	  
1	  
(S
)	  
00
31
	  (
S)
	  
V
67
-­‐3
7	  
(S
2)
	  
ch
ro
ni
c	  
P
A
	  
N
on
e	  
	  
47
	  
13
	  
13
	  
7	  
9	  
10
	  
0.
25
	  (
S)
	  
2	  
(I
)	  
0.
12
5	  
(S
)	  
V
67
-­‐3
6	  
(R
1)
	  
ch
ro
ni
c	  
P
A
	  
N
on
e	  
	  
47
	  
13
	  
13
	  
7	  
9	  
10
	  
>1
6	  
(R
)	  
8	  
(R
)	  
0.
5	  
(I
)	  
V
67
-­‐3
5	  
(R
2)
	  
ch
ro
ni
c	  
P
A
	  
N
on
e	  
	  
47
	  
13
	  
13
	  
7	  
9	  
10
	  
>1
6	  
(R
)	  
8	  
(R
)	  
0.
5	  
(I
)	  
1	  
	  
Table	  S1.	  Characteristics	  of	  thirty	  clinical	  A.	  fumigatus	  isolates	  used	  in	  our	  studies.	  
 
 
 
 
 
 
 
 
94
95
Table 4. Rank of the fiftheen clinical A. fumigatus used for the evaluation of virulence in 
a murine model of disseminated aspergillosis based on the observed CSIs.
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Chapter 7
Summary/Sammenvatting
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Summary
The main aim of the thesis was to explore potential clinical implications of the selection of azole resistance in A. 
fumigatus. Does infection due to azole-resistant A. fumigatus have consequences in terms of the ability to cause 
infection (virulence) and the efficacy of azole drugs? Using an in vivo model of disseminated aspergillosis the virulence of 
isolates harboring various azole resistance mechanisms was investigated. Furthermore, voriconazole and posaconazole 
exposure – response relationships were determined using a range of isolates with varying azole MICs. 
In Chapter 2, we investigated the in vivo efficacy of posaconazole against four clinical A. fumigatus isolates with 
posaconazole MICs ranging from 0.03 to 16 mg/L, as determined by the Clinical and Laboratory Standards Institute 
(CLSI) method M38A, in a non-neutropenic murine model of disseminated aspergillosis. The underlying resistance 
mechanisms of the isolates included substitutions in the cyp51A gene at codon 220 (M220I), codon 54 (G54W), and 
codon 98 (L98H). The last was combined with a 34-bp tandem repeat in the gene promoter region (TR
34
/L98H). The 
control isolate exhibited a wild-type phenotype without any mutations in the cyp51A-gene. We found that survival 
was dependent both on the posaconazole dose and MIC. This also applied to the relationship between the area under 
the plasma concentration–time curve (AUC)/MIC ratio and 14-day survival. Near-maximum survival was reached at an 
AUC/MIC ratio of nearly 1000. 
In Chapter 3, we studied the impact of the cyp51A mutants mentioned in Chapter 1 on the pharmacokinetic and 
pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. The MICs for voriconazole 
ranged from 0.125 to 2 mg/L (CLSI document M38A). Survival for all isolates was dependent on the voriconazole dose 
level, but a better relationship existed for the AUC over 24 h in the steady state divided by the MIC (AUC/MIC ratio) 
or the AUC for the free, unbound fraction of the drug divided by the MIC (fAUC/MIC ratio). The 24 h fAUC/MIC ratio 
showed a clear relationship with effect, with an exposure index for the amount of free drug required for 50% of 
maximum effectiveness (fEI50) of 11.17 at day 7. Maximum effect was reached at values of around 80 to 100. Mice 
infected with an isolate that had an MIC of 2 mg/L required an exposure that was inversely correlated with the increase 
in MIC relative to that of the wild-type control, but due to nonlinear pharmacokinetics, this required only doubling of 
the voriconazole dose. The efficacy of voriconazole for isolates with high MICs for other triazoles, but with voriconazole 
MICs within the wild-type population range was comparable to that for the wild-type control. 
In Chapter 4, we investigated if a mathematical method could be used to determine epidemiological cutoff values 
(ECV) that separate wild-type isolates from isolates with reduced susceptibility to antifungal drugs, thus setting the 
foundation for establishing clinical breakpoints for azole compounds in A. fumigatus. ECVs are usually determined 
by visual inspection of MIC distributions, which lacks objectivity, sensitivity, and statistical robustness, and may be 
difficult, in particular, for extended and complex MIC distributions. We therefore evaluated a statistical method of MIC 
distribution analysis for posaconazole, itraconazole, and voriconazole for 296 A. fumigatus isolates utilizing nonlinear 
regression analysis, normal plot technique, and recursive partitioning analysis, incorporating cyp51A sequence 
data. MICs were determined with CLSI M-38A2 after incubation for 48h and were transformed into log(2)MICs. A 
wide distribution of MICs was found for all azoles, ranging from 0.02 to 128 mg/L with median MICs of 32 mg/L for 
itraconazole, 4 mg/L for voriconazole, and 0.5 mg/L for posaconazole. 65% (192/296) of the isolates had mutations in 
the cyp51A gene with the majority of them (90%) harboring the TR
34
/L98H resistance mechanism. MIC distributions 
deviated significantly from normal distribution (D’Agostino & Pearson omnibus normality test P value <0.001) and 
they were better described with a model of the sum of two Gaussian distributions (R2 0.91-96). Normal plot technique 
revealed a mixture of two populations of MICs separated by MICs of 1 mg/L for itraconazole, 1 mg/L for voriconazole, 
and 0.125 mg/L for posaconazole. Recursive partitioning analysis confirmed these ECVs, since isolates harboring 
cyp51A mutations associated with azole resistance were less than 20%, 20-30%, and >70% when the MICs were lower 
than, equal to, and higher than the above-mentioned ECVs, respectively.
In Chapter 5, we investigated the susceptibility and virulent properties of four A. fumigatus isolates that were serially 
recovered from a patient with chronic granulomatous disease. The first two isolates (1 and 2) were susceptible to 
antifungal azoles, but increased itraconazole, voriconazole, and posaconazole MICs were found for the last two isolates 
(3 and 4). Microsatellite typing showed that the 4 isolates were isogenic, suggesting that resistance had been acquired 
during azole treatment of the patient. An immunocompromised mouse model confirmed that the in vitro resistance 
corresponded with treatment failure. Mice challenged with the resistant isolate 4 (MIC 0.5 mg/L) failed to respond 
to posaconazole therapy, whereas those infected by susceptible isolate 2 (MIC 0.5 mg/L) responded. Posaconazole–
anidulafungin combination therapy was effective in mice challenged with isolate 4. No mutations were found in the 
cyp51A gene of the four isolates. However, expression experiments of the cyp51A showed that the expression was 
increased in the resistant isolates, compared with the azole-susceptible isolates
. 
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The microscopic morphology of the four isolates was similar, but a clear alteration in radial growth and a significantly 
reduced growth rate of the resistant isolates on solid and in broth media was observed compared with isolates 1 and 
2, as well as unrelated wild-type controls. In the mouse model the virulence of isolates 3 and 4 was reduced compared 
with the susceptible ones and the wild-type controls. 
In Chapter 6, we investigated a number of azole resistance mechanisms and their potential accompanying virulence 
changes. We developed a new measure of survival, the composite survival index (CSI) and applied this as a measure of 
the virulence properties of A. fumigatus. Using a novel mathematical model we found a strong correlation between the 
in vitro growth characteristics and survival in vivo expressed as CSI. Our model elucidates how three critical parameters 
(the lag phase (t), decay constant (l), and growth rate (n)) interact with each other resulting in a CSI that correlated with 
virulence. Hence, strains with a long lag phase and high decay constant were less virulent in a murine model of invasive 
aspergillosis, whereas high virulence for isolates with a high CSI was associated in vitro with rapid growth and short lag 
phases. When resistant isolates with cyp51A mutations, which account for the majority of azole resistant aspergillosis 
cases, were investigated we found that the virulence was not compromised compared to azole- susceptible isolates. 
In contrast, the CSI model revealed that a non-cyp51A-mediated resistance mechanism was associated with a lower 
virulence and a dramatic decrease in CSI. Additionally, a general model to predict the CSI was developed which is 
of great importance with regards to animal welfare because a significant reduction in the number of experimental 
animals required can be achieved. Therefore, the CSI model is a promising tool to predict virulence. 
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Samenvatting
Het belangrijkste doel van dit proefschrift was om de mogelijke klinische implicaties van resistentie voor azolen in 
Aspergillus fumigatus te onderzoeken en of azool resistentie in een A. fumigatus stam gevolgen heeft voor diens 
virulentie. Met een in vivo model van invasieve aspergillose werd gekeken naar de virulentie van isolaten met 
verschillende azool resistentiemechanismen en werd er naar de relatie tussen expositie en respons voor voriconazole 
en posaconazole gekeken bij isolaten met verschillende Minimum Remmende Concentraties (MRC’s) voor deze azolen.
In Hoofdstuk 2 onderzochten we de in vivo werkzaamheid van posaconazol tegen vier klinische A. fumigatus isolaten met 
MRCs variërend van 0,03 tot 16 mg/l voor posaconazole in een niet neutropeen muismodel van een gedissemineerde 
aspergillose.
De MRC’s werden bepaald met behulp van de CLSI (Clinical and Laboratory Standards Institute) methode M38A. De 
resisentie mechanismen in deze isolaten waren respectievelijk substitutie in het cyp51A gen op codon 220 (M220I), 
codon 54 (G54W) en codon 98 (L98H). Het laatste isolaat werd gecombineerd met een 34-bp tandem repeat in de 
promoter regio (TR34/L98H). Het controle isolaat was een wild-type fenotype zonder mutaties in het cyp51A-gen. 
We vonden dat de overleving zowel afhankelijk was van de dosis posaconazol als de MRC waarde. Dit gold ook voor 
de relatie tussen de oppervlakte onder de plasmaconcentratie-tijd curve/MRC  (AUC/MRC) ratio en de 14-daagse 
overleving. Door de expositie te combineren met de MRC voor de stam kon een gegeneraliseerde relatie worden 
vastgesteld die gold voor alle onderzochte stammen. De bijna maximale overleving werd bereikt bij een AUC/MRC ratio 
van bijna 1000.
In Hoofdstuk 3 onderzochten we de farmacokinetische (PK) en farmacodynamische (PD) eigenschappen van voriconazol 
van de in hoofstuk 1 genoemde cyp51A mutanten in een gedissemineerde aspergillose muismodel. De MRC voor 
voriconazol varieerde van 0.125 tot 2 mg/l (CLSI document M38A). De overleving voor deze isolaten was afhankelijk 
van de dosis voriconazol, maar ook hier werd een betere relatie gevonden bestaan uit de AUC over 24 uur in de steady 
state gedeeld door de MRC (AUC/MRC ratio) of de AUC.  De relatie tussen de 24 uur fAUC/MRC – de f staat voor vrije, 
niet-eiwit gebinden fractie- en effect liet zien dat de fEI50 (de 50% effectieve PK/PD index) op dag 7 11.17 was. Het 
maximale effect werd bereikt bij waardes tussen de 80 en de 100. Omdat de farmacokinetiek van voriconazole niet 
lineair is, was de relatie van de respons met AUC aanzienlijk beter dan met de dosering zelf. Dit had mede tot gevolg 
dat de dosering die nodig was om een maximaal effect te bereiken bij de stam met een MRC van 2 mg/L veel lager was 
dan verwacht mocht worden op basis van de respons bij stammen met een lage MRC. 
In hoofdstuk 4 onderzochten we of een wiskundige methode kan worden gebruikt om de epidemiologische cut-off 
waarden (ECV) te bepalen zodat we de wildtype isolaten kunnen onderscheiden van de isolaten met een verminderde 
gevoeligheid voor deze antimycotica. ECVs worden meestal bepaald door visueel aflezen van de MRC verdeling, 
objectiviteit, gevoeligheid en statistische degelijkheid ontbreken en dit kan moeilijk zijn, in het bijzonder voor 
uitgebreide en complexe MRC verdelingen. Daarom hebben we een statische methode geëvalueerd voor de analyse 
van de MRC verdeling voor posaconazol, itraconazol en voriconazol voor 296 A. fumigatus isolaten door gebruik te 
maken van een niet-lineaire regressie-analyse, de normal-plot techniek, en recursieve partitie analyse, waarin ook 
cyp51A sequence data werden meegenomen. MRCs werden bepaald met de CLSI M-38A2 methode. Na incubatie 
gedurende 48 uur werden de MRCs omgezet in 2log MRCs. Een brede verdeling van MRCs werd gevonden voor alle 
azolen, variërend van 0.02 tot 128 mg/l met een mediane MRC van 32 mg/l voor itraconazol, 4 mg/l voor voriconazol 
en 0.5 mg/l voor posaconazol.
65% (192/296) van de isolaten hadden mutaties in het cyp51A gen, het merendeel (90%) de TR34/L98H mutatie. De 
MRC verdeling week significant af van de normaal verdeling (D’Agostino & Pearson omnibus normaliteit test P-waarde 
<0,001) en ze waren beter beschreven met een model van de som van twee Gauss-verdelingen (R2 0,91-96). De 
normale plot techniek bleek een mengsel van twee populaties van MRCs te laten zien, gescheiden door MRC’s van 1 
mg/l voor itraconazol, 1 mg/l voor voriconazol en 0.125 mg/l voor posaconazol. Recursieve partitie analyse bevestigde 
deze ECVs, aangezien isolaten met een cyp51A mutatie geassocieerd worden met azool resistentie.
In hoofdstuk 5 onderzochten we de gevoeligheid en de virulentie eigenschappen van vier A. fumigatus isolaten die 
opeenvolgend waren geïsoleerd van een patiënt met chronische granulomateuze ziekte (CGD). De eerste twee isolaten 
(1 en 2) waren gevoelig voor de azolen, maar de laatste 2 (3 en 4) hadden verhoogde MRCs voor itraconazol, voriconazol 
en posaconazol. Bij de microsatelliettypering bleken het isogene isolaten te zijn, wat suggereerde dat resistentie was 
ontstaan tijdens de azool behandeling van de patiënt. Een immunogecompromitteerd muismodel bevestigde de 
implicaties van in vitro resistentie voor behandeling.  Muizen geinfecteerd met het resistente isolaat 4 reageerden niet 
op de behandeling met posaconazol, terwijl muizen besmet met het gevoelige isolaat 2 wel reageerden. 
Posaconazol-anidulafungin combinatie therapie bleek effectief bij muizen besmet met isolaat 4. Er werden geen 
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mutaties gevonden in de cyp51A gen van deze vier isolaten. Echter bij expressie experimenten van cyp51A bleek dat 
de expressie verhoogd was in de resistente isolaten vergeleken met de azool gevoelige isolaten. De microscopische 
morfologie van de vier isolaten was vergelijkbaar, maar bij de resistente isolaten was er een duidelijke verandering 
in de radiale groei en een lagere groeisnelheid op zowel vaste als vloeibare voedingsbodems in vergelijking met de 
isolaten 1 en 2 en de wild-type controles. In het muizenmodel was de virulentie verminderd van de isolaten 3 en 4 ten 
opzichte van de gevoelige stammen en de wild-type controles.
In hoofdstuk 6 onderzochten we een aantal azool resistentiemechanismen en de mogelijk bijbehorende effetten 
op virulentie. Wij hebben een nieuwe effectmaat ontwikkeld voor het meten van de overleving, de samengestelde 
survival index (CSI) en hebben deze als maat voor de virulentie op A. fumigatus toegepast. Met behulp van een nieuw 
wiskundig model vonden we een sterke correlatie tussen de in-vitro groei eigenschappen en de overleving in vivo in 
een invasief aspergillose muizenmodel uitgedrukt als CSI. In ons model is te zien hoe drie kritische parameters (de 
lag-fase (t), vervalconstante (l), en groeisnelheid (n)) een wisselwerking met elkaar hebben die correleert met de CSI. 
Stammen met een lange lag-fase en een hoge vervalconstante bleken minder virulent, terwijl isolaten met een hoge 
CSI een hoge groeisnelheid en een korte lagfase hebben. Bij resistente isolaten met een cyp51A mutaties vonden we 
dat de virulentie niet werd aangetast in vergelijking met de azole-gevoelige isolaten. Dit was in tegenstelling met de 
virulentie van een stam met  een niet door cyp51A veroorzaakte resistentie, die gepaard ging met een zeer lage CSI. 
Daarnaast werd een algemeen model ontwikkeld om de CSI te voorspellen op basis van in- vitro groei karakteristieken. 
Dit is van belang is met betrekking tot het dierenwelzijn omdat door gebruik making van dit model mogelijk een 
significante vermindering van het aantal benodigde proefdieren kan worden bereikt voor bepaalde experimenten. 
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Chapter 8
General Discussion and Future perspectives
106
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Can animal models help to predict treatment success in human infection?
Azole resistance involves diverse underlying molecular mechanisms and the relationship between antifungal drug 
exposures and these mechanisms remains understudied or unknown. Therefore, we performed pharmacokinetic/
pharmacodynamic studies (animal and clinical) in order to understand the clinical impact of antifungal resistance. 
Pharmacodynamics in the context of drug resistance can be used to help define the resistance level that is clinically 
relevant [1,2]. The pharmacodynamic index should result from treatment efficacy studies against organisms with a 
wide variation in MIC [1]. Human pharmacokinetics can then be related to this distribution of MICs. To date, there have 
been no comparable studies for azole-resistant A. fumigatus isolates. 
Although the AUC/MIC or free AUC/MIC ratio has been shown by preclinical animal models to be a better parameter 
than the trough concentrations (C
min
) to monitor efficacy and toxicity for azoles, clinical therapeutic drug monitoring 
(TDM) is principally concerned with the assessment of trough levels for practical reasons. Additionally, clinical data are 
currently insufficient due to the lack of specific correlation of exposure with clinical efficacy and MIC. Correlating the 
pharmacokinetics hAUCs with trough concentrations (clinical data kindly provided by R. Brüggemann) [3] and with the 
experimental pharmacodynamics AUC/MIC allows the prediction of the C
min
, and therefore, AUCs for the highest MIC 
that may be necessary to obtain a high probability of therapeutic success (Figure 1).
Figure 1. Posaconazole (panel A) and voriconazole (panel B) AUC levels show a strong linear correlation to trough 
concentrations. 
For posaconazole, the analysis showed that 60% of the patients had trough concentrations ranging from 1.5 to 4.5 
mg/L, which corresponded to an AUC
0
-
24 
of 30- 96 mg h/L; 20% of patients reached concentrations between 1.4 and 1.9 
mg/L (44-50 mg h/L AUC
0-24
); and 20% of patients showed very low trough levels between 0.8-1.3 mg/L, corresponding 
to AUCs of 28-38 (Table 1; Figure 1)[3]. Previous reports predicted that a mean plasma concentration of 1.25 µg/mL 
in patients would correspond with the best response rate of 75%, whereas a mean plasma concentration of 0.134 µg/
mL corresponded with the lowest response rate of 24% [4]. Andes et al. go even further to suggest that, for patients 
being treated for invasive fungal infection, the trough posaconazole goal should be 1.5 mg/L [5]. Our animal model of 
disseminated invasive aspergillosis indicates both recommended blood levels may be subtherapeutic. To derive this, 
we used the effective pharmacodynamic index (EI) from our animal model that corresponded to 50% and 75% survival 
(EI
50
 and EI
75
) and correlated these with the hAUCs and trough concentrations shown in Figure 1. Accordingly, 75% of 
patients (AUC
0-24 
~ 54 mg h/L) can be optimally treated with C
min
 of ≥ 1.5 mg/L if they are infected by strains with an MIC 
of ≤ 0.06 mg/L (Table 1). If the posaconazole MIC is ≤ 0.5 mg/L the probability of successful treatment is only 50%. Yet, 
it is also possible that trough levels lower than 1.5 mg/L may be adequate to treat other types of aspergillosis. MICs 
have not been reported in the majority of clinical cases or clinical trials and therefore comparisons with the current 
guidelines are challenging (Table 1) [6]. With respect to the previous point regarding the disease, recent findings in a 
neutropenic pulmonary murine model predicted that a near maximum AUC/MIC of 440 mg.h/L or EI
50
 of 167 mg.h/L, 
which is half of the AUC/MIC ratio that was predicted using our model [7]. A significant limitation, however, is that the 
outcome from the Howard study was based on a single strain and not a collection of isolates with a wide variation in 
MIC.
(http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003420.pdf).
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Which animal model best predicts drug efficacy in humans?
To determine whether a key determinant for the conflicting results is the number of strains with different MICs used to 
evaluate drug efficacy, we reanalyzed our data from chapter 2 (Figure 2) by omitting one or two strains with increased 
MICs from the exposure-response curve. Performing the analysis with a single strain was not feasible because there 
were not sufficient data points to obtain a good fit. We found that the exposure-response curve shifted towards lower 
EI
50
 values, approximately 50% lower, as the MIC range narrowed, whereas the EI
60
 and EI
65
 values remained constant 
and EI values greater than EI
65
 increased. The variation in the EI PD endpoint was critically dependent on the steepness 
of the curve (Figure 2) and the EI
50
 was not the constant part possibly because the majority of data points were above 
this value. Thus, the gradient of the slope affected the effective concentrations in the range close to maximum survival 
percentage, which increased when the EI
50
 decreased. Among the three nested curves, the 95% confidence intervals 
showed a significant difference between the EI
50
s, indicating that the accurate model is the one which incorporated 
all four strains (95% CI of EI
50
 = 223-463). Of note, the EI
50
 derived from the curves without one or two strains with 
elevated MICs was in agreement with the value reported by the Howard study, suggesting that the lack of multiple 
strains with a range in MIC values may lead to erroneous conclusions.
Figure 2. The impact of multiple MICs on the prediction of the PD-target. The pharmacodynamic parameter should 
result from treatment efficacy studies against organisms with a wide variation in MIC. 
Another important issue that has emerged from our studies is that the modal MICs of the strain M220I (EUCAST and 
CLSI measurements) after numerous repetitions showed a constant tendency toward to 1 mg/L instead of 0.5 mg/L, as 
reported 3 years ago. We reanalyzed the data using an MIC of 1 mg/L and the Emax model now resulted in an EI
50
 value 
of 178 (Figure 3), which is in agreement with the data of Howard et al [7]. 
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Figure 3. The modal MIC of 1 mg/L for the M220I isolate results in an EI
50
 value similar to that resulted from a neutropenic 
pulmonary murine model of aspergillosis [7,8].
In conclusion, from the aforementioned variations in both models, it is clear – from a statistical and technical point of 
view - that either the half-maximum or near maximum can be employed as equally good predictors for clinical outcome 
if the experimental model is properly conducted. However, from a clinician’s perspective, to enhance the likelihood of 
a successful therapeutic outcome, it may be reasonable to preferentially select the dosing regimen derived for EI
>75
. 
To conduct the experimental models properly, it is necessary to standardize the pharmacodynamic models and two 
key factors must be considered: a) the number of isolates with different MICs and b) a highly reproducible MIC value. 
Unfortunately, the current reference methods of CLSI and EUCAST are not without pitfalls. The main reason for this 
is that the methodologies are not highly reproducible, and it is accepted that MICs may vary within two two-fold 
dilutions. As such a variation has major implications for PK/PD analyses the accuracy of the antifungal testing for 
A. fumigatus needs to be improved. Presently repeated MIC tests should be performed in order to determine the 
geometric mean or modal MIC. 
The analysis shown in Figure 3 suggests that a common EI
50
 value can be obtained despite the use of different 
experimental models [7]. This indicates that the immune status or the route of infection had no significant impact on 
treatment outcome. To further build on the research presented here, it would be useful to reexamine the neutropenic 
pulmonary murine model by using the same isolates as those used in this thesis. 
When we turn to voriconazole, on the other hand, matters become even more complex due to the non-linear 
pharmacokinetic properties [9,10,11,12]. The correlation between our preclinical data and the clinical data shown in 
Figure 1 revealed that in 30% of patients trough levels were  < 1 mg/L (AUC
0-24
 28-41 mg.h/L), for 40% ≥1.2 to 1.8 mg/L 
(AUC
0-24
 52-74 mg.h/L), and for 30% ≥2.3 to 2.8 mg/L (AUC
0-24
 78-96 mg.h/L) [13]. Previous studies of humans showed 
that standard-dose oral voriconazole results in a total AUC
0–24 
value of 18 to 23 mg h/L [14]. An oral dose of 200 mg 
twice daily would result in a free drug AUC of 8.4 µg h/ml [15]. For hematopoietic stem cell transplant (HSCT) recipients, 
the median total AUC
0–24
 was found to be approximately 70 mg h/L on study day 7 and 50 mg h/L on day 14 [13], which 
would correspond to an fAUC of approximately 21 and 15 mg h/L, respectively, based on a free fraction of 29.87%. 
Hence, for infections of MIC ≤ 1 mg/L (EI
80
), trough concentrations greater than 2.3 mg/L, which correspond to an 
AUC
0-24 
of approximately 80 mg.h/L, are necessary to reach optimal treatment. The effective pharmacodynamic indices 
for voriconazole are listed in Table 1. Infections with MIC of >1 mg/L may require dose adjustments exceeding the non-
toxic range of 4-5 mg/L. Our findings confirm and expand upon previous clinical data that suggest mean voriconazole 
concentrations for optimal outcomes reaching 3–4 mg/l (website: www.fda.gov/ohrms/dockets/AC/01/briefing/ 
3792b2_01_Pfizer.pdf). Our data are also in line with Smith and colleagues, who categorized random concentrations of 
less than 2.05 mg/l to suboptimal levels, for patients with invasive aspergillosis, [16]. 
On the contrary, Pascual contradicts these data by defining the relationship between trough concentrations and 
successful outcome using a logistic regression model in which a trough level of merely 1 mg/l was associated with a 
generous 70% probability of a successful outcome [17]. The upper range most likely at 5–6 mg/L is associated with 
toxicity [17]. Without TDM, the precise therapeutic targets for voriconazole based on dose alone, remain unclear 
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because variability in plasma concentrations and systemic exposure varies >100-fold between patients receiving the 
same dose and the coefficient of variation of the AUC has been estimated to be 74-100% [16,17]. 
It is becoming clearer the extent to which the design of a study or the choice of an experimental model can affect the 
determination of the efficacy of drugs. In this thesis, to study the efficacy of azoles, we employed an immunocompetent 
murine model of disseminated aspergillosis by using the intravenous infection route. The selection of the proper animal 
model is crucial before moving to the infected patient and relating the preclinical results with clinical perspectives in 
humans because it may lead to different susceptibility breakpoints or erroneous treatment. Hence, for preclinical drug 
efficacy investigations, a comparison between pulmonary and systemic infection is necessary with respect to possible 
variations in the pharmacokinetic and pharmacodynamic properties of antifungal agents. Drug delivery to the site of 
infection and tissue penetration may vary; this results in different modes of action against the same organism when used 
in different murine models of aspergillosis [18]. For instance, micafungin alone, or in combination, acts synergistically 
in a systemic model [19], and shows no synergistic activity in a pulmonary model of infection [20]. Furthermore, in an 
experimental pulmonary aspergillosis model, the use of voriconazole in combination with anidulafungin resulted in a 
strong synergistic effect that caused hyphal damage of A. fumigatus [21]. The efficacy of the combination was superior 
to the effects of the single agents and untreated controls [21]. In contrast, combining both agents did not significantly 
improve the therapeutic outcome in an experimental model of advanced invasive pulmonary aspergillosis [22].
Combining the studies reported herein reveals that comparisons between antifungal compounds with respect to 
efficacy have been hindered and reproduction of data is lacking due to marked indifferences between animal models. 
Therefore, it is necessary to standardize and validate the animal models. This can be achieved by building upon a 
common consensus for the route of infection, size of inoculum, immune status, the animal or species used for infection, 
the sample size, timing of the administration and dosing regimen of the study treatment, establishment of a control 
strain for the placebo groups, determination of virulent properties of a strain, establishment of the number of different 
MICs required in a dose/exposure response curve. All these determinants affecting the experimental outcome will be 
adjusted based on the underlying disease. Finally, the best animal model will derive from giving the best correlation 
with clinical outcome. Accordingly, a standardized pulmonary or central nervous system (CNS) model of aspergillosis 
(predefined standard model) will receive a drug prophylactically (determined by the protocol) or post disease progress 
(determined by the protocol) and data can be then compared with other drugs reported in the literature and the best 
efficacy can be determined. To generate such standardized animal models that mimic the human pathogenesis and 
treatment, countermeasures are needed from an inter-disciplinary international consortium, similar to that available 
for the in vitro MIC testing (EUCAST and CLSI committee), that will define the validation criteria and the aspects of the 
design of a study for the different aspergillosis models. 
On the other hand, translational failure between animal models and clinical trials may also occur due to insufficient 
statistical power to detect a true benefit of the treatment under study in a clinical trial [23]. Shortcomings are mostly 
the cause of these underdesigned studies. Worp and colleagues reported that also inadequate methodological 
approaches in controlled clinical trials were associated with bias [23]. Therefore, evaluation of the quality of the design 
and methodology standardization of clinical trials by independent international boards of PK/PD experts is required. 
Minimizing these limitations so that the results obtained are closer to the true values will allow us to optimize treatment 
for the benefit of the patients 
Therapeutic drug monitoring
Obviously, such high discrepancies highlight that the development of clinical breakpoints, which are essential for the 
prediction of clinical outcome, for both azoles is not as straightforward as one may have thought. This is apparent 
when looking at retrospective pharmacokinetic studies in patients with probable or proven invasive aspergillosis or 
other fungal infections and demonstrates that great inter- and intrapatient variability in plasma concentrations exists. 
Aside from erratic absorption of the drugs, other factors such as drug-drug interactions, underlying disease, genetic 
polymorphisms within one or more patient populations [24], neutropenic stage, and body weight also play a role 
[12,25]. 
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Table 1. Summary of our recommendations for the treatment of disseminated invasive aspergillosis compared with 
current guidelines.
PK/PD
Indices
Guidelines for treatment of Mycosis
Recommendations for treatment of 
disseminated invasive Aspergillosis
Posaconazole1 Voriconazole2 Posaconazole Voriconazole
Therapeutic C
min
1.2 mg/L1 [6] >1 to >2 mg/L >1.5 mg/L >2.3 to >2.8 mg/L
Therapeutic 
AUC
0-24
30 mg h/L1[6]
No data for
A. fumigatus
≥ 54 mg h/L( EI
75
)
≥ 90 mg h/L (EI
50
)
≥ 80 mg h/L (EI
75-80
)
≥ 74 mg h/L (EI
50
)
3MIC (mg/L) 
(Clinical 
Breakpoints)
No data No data
≤ 0.06 (EI
75
)
≤ 0.5 (EI
50
)
≤ 1 (EI
75-80
)
≤ 2 (EI
50
)
1Posaconazole and Aspergillus spp.: Rationale for the EUCAST clinical breakpoints, version 1.0 
2EUCAST guidelines for candidiasis. Voriconazole: Rationale for the EUCAST-AFST clinical breakpoints, version. 2.0 for 
candidiasis. 3MIC estimates for optimal therapy against disseminated invasive aspergillosis.
The plasma concentrations that are required to achieve the pharmacodynamic target to produce these treatment 
endpoints is related to the organism MIC and understanding the limits of azole therapy in relation to the MIC 
is crucial to guide optimal antifungal treatment. Given that the dose does not always correlate with an expected 
plasma concentration, to avoid toxicities, and furthermore to monitor the effect of the interaction of diverse agents, 
TDM is recommended be performed on a routine basis although evidence is lacking. The importance of voriconazole 
TDM in severely ill patients with invasive mycoses has been previously reported [17,26,27] and it can be of great 
benefit for patients because, as mentioned earlier, multiple intrinsic and extrinsic factors may influence voriconazole 
pharmacokinetics [27]. Moreover, increasing exposure for voriconazole is feasible and therefore it may be a therapeutic 
option for isolates with an MIC less than 1 mg/L, but the risk of toxicity may also increase [17]. 
The Marchetti group refers to two points as critical to prevent treatment failures and toxicity which can be only achieved 
with the assistance of TDM. Accordingly, voriconazole trough levels should a) be sustained within the therapeutic 
interval of 1–5.5 mg/L and b) this must occur during the first week of therapy. The authors emphasize the point that 
it is unclear what the best therapeutic option would be if the infections were caused by strains with an MIC out of the 
range of the WT distribution. 
Regarding posaconazole, TDM should be performed only because the erratic absorption results in inconsistent levels 
in blood that leads to suboptimal treatment [28]. Clinicians should ensure that patients attain the feasible standard 
exposure necessary to prevent fungal infections if the infecting strain is a WT (MIC <0.06 mgL). The role of posaconazole 
in the antifungal arsenal should be maintained as that of prophylaxis and not as that of primary treatment against 
invasive aspergillosis, in accordance with the results presented herein. 
Therefore, striving to increase the standard dosing regimen and thereby the exposure may have some effect, but it may 
be clinically more useful, safer and cheaper to find other alternatives to overcome azole resistance, such as to switch 
to polyenes, echinocandins, new antifungal compounds or to use combination therapy. 
Strategies to manage azole resistant Aspergillus disease
Our studies show that azoles are less effective in treating azole-resistant aspergillosis. The results of in vitro studies and 
multiple animal models suggest that, to overcome azole resistance or generally to improve treatment of patients with 
invasive aspergillosis, it may be reasonable to add a second agent to azoles, such as an echinocandin, for increased 
activity against azole-resistant A. fumigatus [29,30,31] (Figure 4).
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Figure 4. Suggestive strategy for the management of azole resistant IA
 
For instance, in a retrospective study with lung-transplant patients, a combination of voriconazole and caspofungin 
was acceptably safe and was associated with good clinical outcome in almost all patients [32]. Patients were treated for 
proven or probable invasive aspergillosis and the majority of them had a complete response. Additionally, caspofungin 
in combination with voriconazole provided cover against Aspergillus infection during the period when voriconazole may 
be at subtherapeutic levels [32]. Conversely, in a recent prospective randomized study, the combination of voriconazole 
with anidulafungin showed no synergism. The primary analysis of the clinical trial was to compare mortality rates 
six weeks after initiation of treatment in patients with a diagnosis of proven or probable invasive aspergillosis [33]. 
Treatment with the combination of voriconazole and anidulafungin resulted though in a lower mortality rate compared 
to voriconazole monotherapy, however, this improvement was not statistically significant [33]. If we assume that in the 
randomized study patients would have been infected with wild type isolates, then this trial is in conflict with a recently 
presented non-neutropenic murine model of disseminated aspergillosis, in which synergism was found with wild-type 
strains, whereas additivity was observed with the voriconazole resistant isolate (TR
34
/L98H mutant, MIC = 4 mg/L) [34]. 
Regardless, the data from the clinical trial have not yet been published and it is not possible to determine the source 
of these conflicting data. Given all these considerations, as a precaution, voriconazole with echinocandin would be a 
logical combination especially in the setting of primary therapy when the susceptibility of the isolate is unknown.
Preliminary data of an additional alternative to treat azole resistance also suggested the combination of posaconazole 
and caspofungin against systemic aspergillosis [35]. In a recent monocentric retrospective study, the efficiency and 
safety of caspofungin with posaconazole was evaluated in immunocompromised patients [36]. A study of 31 hospitalized 
haematopoietic stem cell transplant recipients with refractory invasive aspergillosis treated with caspofungin and 
posaconazole were assessed by signs, symptoms and the degree of pulmonary infiltrate regression, following the 
EORTC criteria. A favorable response was seen in 77% of patients [36]. The combination therapy was well tolerated 
and no patient terminated treatment because of toxicity. Furthermore, recently reported in vitro studies showed that 
the combination of posaconazole and caspofungin was synergistic against A. fumigatus isolates with different azole-
resistant mechanisms [29]. The strongest synergy was found for isolates harboring TR and M220 mutations at clinically 
achievable serum concentrations. The synergism resulted in a 50% reduction in growth. Although there are no data 
for posaconazole in the primary therapy of invasive aspergillosis and this antifungal compound is used primarily as 
salvage therapy or prophylactically, enough clinical and experimental evidence is being accumulated that it is worth 
investigating whether this combination may be clinically useful for the primary therapy of azole-resistant Aspergillus 
diseases. An unexpected finding was the observed differences in drug interactions between the different resistance 
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mechanisms [29]. This requires further research into the underlying mechanism. 
Finally, whether combinations of polyenes with echinocandins or azoles are a good therapeutic option remains unclear 
and arguable. An in vivo–in vitro correlation was reported for the treatment of aspergillosis with a combination of 
amphotericin B and caspofungin. The combination resulted in a higher survival rate and more favorable pathological 
findings than those obtained with caspofungin or amphotericin B therapy alone [37,38]. In an experimental model of 
central nervous system aspergillosis, the efficacy of micafungin, caspofungin, voriconazole, conventional amphotericin 
B, ambisome and Abelcet as monotherapy or in different combinations was tested. Only ambisome in combination 
with voriconazole was superior for treatment of CNS aspergillosis. In contrast to these experimental models, a clinical 
study with 70 hematological malignancy patients revealed that the combination of L-AMB and echinocandins offered 
no advantage in terms of improved response or reduced mortality over either drug alone [39].
Resistance and the risk of virulence ‘gain’
The two significant mechanisms involved in the determination of the outcome of microbe infection are antimicrobial 
virulence and its resistance to antimicrobial compounds. To date, the definition of virulence has been confused with 
pathogenicity and this lack of clarity and consistency leads to critical debates between investigators within the same or 
other disciplines [40,41,42]. Understanding the meaning of virulence and pathogenicity is crucial for the employment 
of the appropriate experimental models. The term virulence is used to indicate the degree of pathogenicity between 
different strains belonging to the same species, and is defined as the capacity of a microbe to cause a pathological 
response or damage in a host [40,41,42]. Strains within the same species can exhibit different levels of virulence. The 
term pathogenicity comprises all those mechanisms that allow the microorganisms to cause infection and it depends 
on numerous factors. Some of these factors are related to the host and its immunity, and others are related to the 
microorganism: infectious doses, microbial attributes defense mechanisms, and resistance to the host [41,42]. 
In addition to appropriate definitions of pathogenicity and virulence, the correct tools for their measurement must be 
developed and implemented [40]. Thus far, three parameters are commonly used as measures from dose– response 
assays: SD
50
 or SC
50
, the relevant dose or concentration that results in 50% survival of the host, and the ST
50
 which is 
the time it takes to obtain 50% survival. Moreover, it is proposed that pathogenicity is best measured by SD
50
 obtained 
through while the LD
50 
factor obtained by injection assays measures virulence [40]. 
Taking into consideration all these critical points regarding the definition and measurement of virulence, a new 
composite endpoint of survival (CSI, Composite Survival Index) was developed that comprises both survival (%SUR) and 
median survival time (MST). In our experimental murine model virulence expressed as CSI was in strong correlation 
with the fungal growth in vitro. Based on this relationship and by using a novel mathematical model, we investigated 
whether cyp51A-mediated azole resistance has an effect on the “virulent” attributes of A. fumigatus or fitness. Fitness 
is defined as the contribution of genes to future generations in a given environment over a defined period of time [43]. 
Several studies showed that spore production, spore decay, spore settlement, spore germination, and mycelia growth 
rate were important fitness components for fungi [44]. Since all these factors play an important role for the capacity 
of a microbe to infect and maintain in a host, it is fair to expect that virulence is also a component of fitness. From 
an evolutionary point of view fitness, including virulence, is closely related to resistance. This relationship exists as 
follows: a) single genes are associated with both virulence and resistance, and b) the acquisition of resistance results in 
direct/indirect induction of genes responsible for virulence, then a network appears that has a synergistic role. In both 
cases the process used for fitness restoration is a crucial strategy as it is associated with microbial survival. 
In chapter 6, our findings infer that cyp51A azole-resistant A. fumigatus isolates can retain or restore their virulence, 
indicating that the ability of resistant isolates to cause disease is similar to that of susceptible isolates. All cyp51A 
resistant mutants showed similar growth and consequently virulence to wild type susceptible isolates. Likewise, 
phenotypic changes related to growth and MIC, were reported in a recent study where itraconazole resistance was 
induced in vitro. Interestingly, mutants that derived at the fifth propagation transfer from itraconazole-containing 
medium expressed low MICs and had reduced growth rates, while those derived from the 10th transfer showed not 
only high levels of itraconazole resistance but also higher growth rates than the parental strain [45]. Apparently, long-
term exposure in the presence of itraconazole was necessary to impose fitness restoration or even virulence gain; yet, 
these strains were observed only at low frequencies. Additionally, these few isolated itraconazole-resistant strains 
presented multiple resistance mechanisms such as cyp51A substitutions (G54R and M220I) and the drug efflux pumps 
Afumdr3, Afumdr4, and AtrF, indicating their partial involvement in the development of resistance. Although previous 
investigations implied that fungal efflux pumps played a role in both fungal pathogenicity and multi-drug resistance, 
comparable studies lacked clinical cyp51A isolates [46]. Knowledge in this area would lead to a better understanding of 
the evolutionary tendency toward azole resistance and thereby affiliated fitness costs and advantages. 
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In our study, in contrast to cyp51A mutants, acquisition of multi-azole resistance in a set of isogenic isolates with 
mutations in the HapE subunit of a transcription factor was associated with slow growth, which resulted in reduced 
virulence compared to the susceptible parental strains. The reason why these multi-azole highly resistant strains are 
less virulent and slower in growth than the cyp mutants or the susceptible isolates, might be related to the HapE muta-
tion or be because they were not exposed to the new conditions for the time required for adaptation and restoration 
of fitness. In microbes, usually, fitness cost or advantage occurs by compensatory second-site mutations; a strong 
evolutionary trigger for interstrain variability [47,48]. De Visser reported that certain mutations can elevate the spon-
taneous mutation rate and can accelerate evolutionary adaptation [49]. Cells containing such mutations are known as 
mutators and cells lacking these mutations with lower mutation rates are referred to as nonmutators. In yeasts, similar 
to bacteria, when mixed populations of mutators and nonmutators were exposed to novel conditions, then mutators 
outcompeted nonmutators [50,51]. Even if nonmutator populations are present in high frequency and only a few mu-
tators are present, the latter would dominate because they can acquire beneficial mutations; a phenomenon known as 
hitchhiking [52]. Under the right conditions in asexual contests between nonmutator and mutator strains, the mutator 
is often the winner. Therefore, although mutators may appear at low frequency they keep a protagonistic role in the 
divergence of fitness during evolution, especially in populations where sex is rare [47,51]. This mutator theory may 
also be an explanation as to why the TR
34
/L98H mutation in A. fumigatus is the dominant resistance mechanism in the 
Netherlands. The TR
34
/L98H mechanism was recovered in Europe from environmental air sampling and from patient 
rooms, and therefore, in addition to the development of resistance due to long-term exposure of patients to azoles, 
a second route of infection through environmental isolates was proposed [53,54,55,56]. Accordingly, these strains 
might have become resistant to 14a-demethylase inhibitors (DMIs) by the use of fungicides in agricultural practice 
[57]. Environmental fungal strains with secondary resistance to DMIs may preserve their fitness or even restore it by 
accumulating mutations because any fitness loss would be an important disadvantage when competing with wild type 
field isolates. Moreover, recently we performed a comparative study based on the growth traits of approximately one 
hundred TR
34
/L98H and wild types isolates. We found that clinical A. fumigatus isolates with the TR
34
/L98H mechanism 
had a significantly higher CSI of 2.26% compared to wild type susceptible strains indicating to be more virulent than 
wild types. A recently developed theory reported by Snelders et al. stated that the TR
34
/L98H mechanism may appear 
to be dominant because sexual reproduction of A. fumigatus occurs under very special environmental circumstances 
and conditions at specific geographical locations [58,59]. This speculation may be supported by previous studies in A. 
nidulans. Shoustra et al, compared the rate of adaptation to a novel environment between haploid and isogenic diploid 
strains of A. nidulans over 3,000 mitotic generations. 
Interestingly, diploid strains that reverted to haploidy following parasexual recombination, reached the highest fitness 
[47]. Apparently, this occurred due to the accumulation of recessive mutations in diploid nuclei, some of which showed 
their combined beneficial effect in haploid recombinants. Therefore, with respect to the TR
34
/L98H resistant strains, 
beneficial mutations may have appeared early in competitions won by diploid mutators in different environmental 
conditions conferring thereby a large selective fitness advantage for the fungus. Thus, competition experiments 
under various stress conditions and environmental settings in A. fumigatus are necessary because they would provide 
more insight in understanding the mechanisms that lead to induction, preservation or gain of dominant mutations. 
Additionally, identifying the fitness attributes that make one resistant genotype a strong competitor and more persistent 
towards other resistant mechanisms is very important for the improvement of diagnostic tools and the management 
of azole resistance in clinical practice as Aspergillus undergoes mutations and selection during infection [60]. For 
example, the HapE isogenic mutants rendered resistant from azole susceptible within 17 weeks and they revealed 
hundreds of new SNPs whereby 22 were most significant for resistance [61]. The mutation rate and its influence under 
stress conditions (drug, host response, nutrition availability etc) in A. fumigatus in unknown. There is evidence that 
the variation in mutation rate is correlated with fitness, such that low-fitness microbes have higher mutation rates. 
The relationship between fitness and mutation rate is dependent on how microbes can adapt under “normal” or 
stress conditions. Thus, inducible mutation rates will be favored by natural selection because low mutation rates are 
more beneficial under normal conditions, but greatly increased rates are more favorable under stressful conditions 
[62]. Future research should focus on the strategies that aspergillus has to survive in the hostile environment of the 
human host. The lack of necessary information from genomics in the mycology field has hampered the progress of 
developing diagnostic methods to test for resistance, to define the relationship between genotype and phenotype, and 
consequently, to optimize treatment. Combining the genomic dynamics and the CSI may be a useful tool to correlate 
genetic changes to virulence phenotype and resistance. 
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First,	  I	  would	  like	  to	  thank	  God.	  
Glory	  to	  the	  Father,	  and	  to	  the	  Son,	  and	  to	  the	  Holy	  Spirit,	  now	  and	  ever,	  and	  to	  the	  ages	  of	  
ages.	  Amen.	  	  
The	  Father	  is	  my	  hope.	  The	  Son	  is	  my	  refuge.	  The	  Holy	  Spirit	   is	  my	  protection.	  Holy	  Trinity,	  
glory	  to	  You!	  
“Ἐλέησον	  μέ,	  ὁ	  Θεός,	  κατὰ	  τὸ	  μέγα	  ἔλεός	  σου	  καὶ	  κατὰ	  τὸ	  πλῆθος	  τῶν	  οἰκτιρμῶν	  σου	  ἐξάλειψον	  τὸ	  
ἀνόμημά	  μου.	  Ἐπὶ	  πλεῖον	  πλῦνον	  μὲ	  ἀπὸ	  τῆς	  ἀνομίας	  μου	  καὶ	  ἀπὸ	  τῆς	  ἁμαρτίας	  μου	  καθάρισον	  
μέ.	  Ὅτι	  τὴν	  ἀνομίαν	  μου	  ἐγὼ	  γινώσκω,	  καὶ	  ἡ	  ἁμαρτία	  μου	  ἐνώπιόν	  μου	  ἐστὶ	  διαπαντός.	  Σοὶ	  μόνω	  
ἥμαρτον	  καὶ	  τὸ	  πονηρὸν	  ἐνώπιόν	  σου	  ἐποίησα,	  ὅπως	  ἂν	  δικαιωθῆς	  ἐν	  
τοὶς	  λόγοις	  σου,	  καὶ	  νικήσης	  ἐν	  τῷ	  κρίνεσθε	  σέ.	  ἰδοὺ	  γὰρ	  ἐν	  ἀνομίαις	  
συνελήφθην,	   καὶ	   ἐν	   ἁμαρτίες	   ἐκίσσησε	   μὲ	   ἡ	   μήτηρ	   μου.	   Ἰδοὺ	   γὰρ	  
ἀλήθειαν	   ἠγάπησας,	   τὰ	   ἄδηλα	   καὶ	   τὰ	   κρύφια	   της	   σοφίας	   σου	  
ἐδήλωσας	  μοί.	  Ραντιεῖς	  μὲ	  ὑσσώπω,	  καὶ	  καθαρισθήσομαι.	  Πλυνεῖς	  μέ,	  
καὶ	   ὑπὲρ	   χιόνα	   λευκανθήσομαι.	   Ἀκουτιεῖς	   μοὶ	   ἀγαλλίασιν	   καὶ	  
εὐφροσύνην,	   ἀγαλλιάσονται	   ὀστέα	   τεταπεινωμένα.	   Ἀπόστρεψον	   τὸ	  
πρόσωπόν	   σου	   ἀπὸ	   τῶν	   ἁμαρτιῶν	   μου	   καὶ	   πάσας	   τᾶς	   ἀνομίας	   μου	  
ἐξάλειψον.	   Καρδίαν	   καθαρὰν	   κτίσον	   ἐν	   ἐμοί,	   ὁ	   Θεός,	   καὶ	   πνεῦμα	  
εὐθὲς	  ἐγκαίνισον	  ἐν	   τοὶς	  ἐγκάτοις	   μου.	  Μὴ	  ἀπορρίψης	   μὲ	  ἀπὸ	   τοῦ	  
προσώπου	   σου	   καὶ	   τὸ	   πνεῦμα	   σου	   τὸ	  ἅγιον	   μὴ	  ἀντανέλης	  ἀπ'	  ἐμοῦ.	  
Ἀπόδος	  μοὶ	  τὴν	  ἀγαλλίασιν	  τοῦ	  σωτηρίου	  σου	  καὶ	  πνεύματι	  ἠγεμονικῶ	  
στήριξον	   μέ.	   Διδάξω	   ἀνόμους	   τᾶς	   ὁδούς	   σου	   καὶ	   ἀσεβεῖς	   ἐπὶ	   σὲ	  
ἐπιστρέψουσι.	  Ρύσαι	  μὲ	  ἐξ	  αἱμάτων,	  ὁ	  Θεὸς	  ὁ	  Θεὸς	  τῆς	  σωτηρίας	  μου.	  
Ἀγαλλιάσεται	  ἡ	   γλώσσα	  μου	  τὴν	  δικαιοσύνην	  σου.	  Κύριε,	   τὰ	   χείλη	  μου	  
ἀνοίξεις	   καὶ	   τὸ	   στόμα	   μου	   ἀναγγελεῖ	   τὴν	   αἴνεσίν	   σου.	   Ὅτι	   εἰ	  
ἠθέλησας	  θυσίαν,	  ἔδωκα	  ἂν	  ὁλοκαυτώματα	  οὐκ	  εὐδοκήσεις.	  Θυσία	  τῷ	  
Θεῷ	   πνεῦμα	   συντετριμμένον,	   καρδίαν	   συντετριμμένην	   καὶ	  
τεταπεινωμένην	   ὁ	   Θεὸς	   οὐκ	   ἐξουδενώσει.	   Ἀγάθυνον,	   Κύριε,	   ἐν	   τὴ	  
εὐδοκία	  σου	   τὴν	   Σιῶν,	   καὶ	   οἰκοδομηθήτω	   τὰ	   τείχη	  Ἱερουσαλήμ.	   Tότε	  
εὐδοκήσεις	   θυσίαν	   δικαιοσύνης,	   ἀναφορὰν	   καὶ	   ὁλοκαυτώματα.	   Τότε	  
ἀνοίσουσιν	  ἐπὶ	  τὸ	  θυσιαστήριόν	  σου	  μόσχους.” (psalm 50) 
“Υπεραγία	  Θεοτόκε,	  γλυκιά	  μανούλα	  μας,	  σώσον	  ημάς’	  
	  
Παππούλη	  μου	  σ’	  ευχαριστώ	  μέσα	  από	  τα	  βάθη	  της	  καρδιάς	  μου	  
για	  τις	  προσευχές,	  τις	  συμβουλές	  και	  για	  την	  ψυχική	  δύναμη	  και	  καθοδήγηση!	  	  
Πατερ	  Παντελεημων	  ευχαριστώ	  για	  τις	  προσευχές	  σας	  και	  τη	  συμπαράστασή	  σας.	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